Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.12688/f1000research.8352.1 http://scihub22266oqcxt.onion/10.12688/f1000research.8352.1 C4916986!4916986!27347394     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27347394.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       F1000Res 2016 ; 5 (ä): ä Nephropedia Template TP {{tp|p=27347394|t=2016. Recent advances in primary Sjogren s syndrome |pdf=|usr=}}{{27347394}} gab.com Text Recent advances in primary Sjogren s syndrome JO: F1000Res http://www.kidney.de/pget.php?&tw=1&pmid=27347394 #FOAvip Primary Sjögren?s syndrome, a chronic inflammatory process, is among the most commonly occurring rheumatologic diseases. The clinical hallmark of this disease is exocrine gland dysfunction, resulting predominately in dry eyes and dry mouth. However, the disease often extends beyond the exocrine glands to seriously affect other organs systems, such as the lungs, kidneys, and nervous system. Moreover, patients with primary Sjögren?s syndrome develop non-Hodgkin?s B cell lymphoma at a substantially higher rate than the general population. New research has improved our understanding of disease mechanisms, with notable advances in our knowledge about the genetic susceptibility of disease, the molecular details of the chronic inflammatory response in the salivary glands, and the complex role of the type 1 interferon pathway. The pipeline of drugs under development for the treatment of primary Sjögren?s syndrome is enriched with novel biologics and small molecular entities targeting the pathogenic process. Herein, we summarize the latest advances in elucidating the pathogenesis of primary Sjögren?s syndrome and highlight new drugs in clinical development aiming to reverse the glandular dysfunction and favorably impact the systemic features of this disease. Twit Text FOAVip Recent advances in primary Sjogren s syndrome ????F1000Res http://www.kidney.de/pget.php?&tw=1&pmid=27347394 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27347394 #FOAvip English Wikipedia <ref>{{Cite pmid|27347394}}</ref> Recent advances in primary Sjogren s syndrome #MMPMID27347394 Holdgate N; St.Clair EW F1000Res 2016[]; 5 (ä): ä PMID27347394show ga Primary Sjögren?s syndrome, a chronic inflammatory process, is among the most commonly occurring rheumatologic diseases. The clinical hallmark of this disease is exocrine gland dysfunction, resulting predominately in dry eyes and dry mouth. However, the disease often extends beyond the exocrine glands to seriously affect other organs systems, such as the lungs, kidneys, and nervous system. Moreover, patients with primary Sjögren?s syndrome develop non-Hodgkin?s B cell lymphoma at a substantially higher rate than the general population. New research has improved our understanding of disease mechanisms, with notable advances in our knowledge about the genetic susceptibility of disease, the molecular details of the chronic inflammatory response in the salivary glands, and the complex role of the type 1 interferon pathway. The pipeline of drugs under development for the treatment of primary Sjögren?s syndrome is enriched with novel biologics and small molecular entities targeting the pathogenic process. Herein, we summarize the latest advances in elucidating the pathogenesis of primary Sjögren?s syndrome and highlight new drugs in clinical development aiming to reverse the glandular dysfunction and favorably impact the systemic features of this disease. äRecent advances in primary Sjogren s syndrome (epmc).pdf DeepDyve Pubget Overpricing